Scarica l'app Stockscreener
72.58
1.78%
1.27
Pre-mercato:
73.00
0.42
+0.58%
Precedente Chiudi:
$71.31
Aprire:
$69.87
Volume 24 ore:
869.65K
Relative Volume:
0.63
Capitalizzazione di mercato:
$49.43B
Reddito:
-
Utile/perdita netta:
$-153.72M
Rapporto P/E:
-36.29
EPS:
-2
Flusso di cassa netto:
$-103.81M
1 W Prestazione:
+7.48%
1M Prestazione:
+23.18%
6M Prestazione:
+90.55%
1 anno Prestazione:
+458.31%
Intervallo 1D:
$69.87
$72.89
Intervallo di 1 settimana:
$66.13
$72.89
Portata 52W:
$11.39
$74.18
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Nome
Verona Pharma Plc Adr
Settore
Industria
Telefono
011-44-0-2032834200
Indirizzo
3 MORE LONDON RIVERSIDE, LONDON
Confronta VRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
72.58 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
|
ONC
Beigene Ltd Adr
|
233.37 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.66 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2632 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.54 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Iniziato | TD Cowen | Buy |
| 2025-04-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Iniziato | ROTH MKM | Buy |
| 2024-10-03 | Iniziato | Wells Fargo | Overweight |
| 2023-05-22 | Ripresa | Jefferies | Buy |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-08-26 | Iniziato | Piper Sandler | Overweight |
| 2021-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Jefferies | Buy |
| 2020-08-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-18 | Iniziato | BTIG Research | Buy |
Mostra tutto
Verona Pharma Plc Adr Borsa (VRNA) Ultime notizie
Market Update: Verona Pharma Plc ADR (VRNA) Sees Negative Movement, Closing at 69.14 - DWinneX
Verona Pharma Plc ADR (NASDAQ: VRNA): An Enticing Stock To Watch - Stocksregister
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 - GlobeNewswire Inc.
Verona Pharma’s general counsel sells shares worth $234,126 By Investing.com - Investing.com India
Verona Pharma director Vikas Sinha sells $178,416 in stock By Investing.com - Investing.com South Africa
Verona Pharma’s general counsel sells shares worth $234,126 - Investing.com
Verona Pharma Plc ADR (VRNA)’s Market Momentum: Closing Strong at 72.07, Down -1.56 - DWinneX
What is Verona Pharma Plc ADR (VRNA) Stock Return on Shareholders’ Capital? - Sete News
Verona Pharma Plc ADR [VRNA] Stock trading around $73.21 per share: What’s Next? - dbtnews.com
VRNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Watch this stock’s price performance: Verona Pharma Plc ADR (NASDAQ:VRNA) - uspostnews.com
Verona Pharma ADR earnings beat by $0.05, revenue topped estimates - Investing.com UK
Verona Pharma Plc ADR (NASDAQ: VRNA) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
TD Cowen starts Verona Pharma stock at Buy, sets $100 target - Investing.com
Verona Pharma Shareholders Approve All Proposals at AGM By Investing.com - Investing.com South Africa
Verona Pharma Shareholders Approve All Proposals at AGM - Investing.com
A significant driver of top-line growth: Verona Pharma Plc ADR (VRNA) - Sete News
Is Astrazeneca plc ADR (AZN) positioned for future growth? - Sete News
Verona Pharma Plc ADR [VRNA] Records 50-Day SMA of $62.73 - knoxdaily.com
Tencent Music Entertainment Group ADR [TME] Officer makes an insider purchase of 1,036,363 shares worth 14.87 million. – Knox Daily - knoxdaily.com
TAL Education Group ADR [TAL] Officer makes an insider purchase of 24,041 shares worth 0.28 million. - knoxdaily.com
Ratios Uncovered: Breaking Down Verona Pharma Plc ADR (VRNA)’s Trailing Twelve Months Metrics - DWinneX
Verona Pharma Plc ADR (VRNA) is a good investment, but the stock may be overvalued - uspostnews.com
What is the investor’s view on Marriott Vacations Worldwide Corp (VAC)? - uspostnews.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com
Financial Health Report: Alamos Gold Inc (AGI)’s Ratios Tell a Tale - DWinneX
Cantor Fitzgerald sets $80 target on Verona Pharma stock By Investing.com - Investing.com South Africa
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit undervalued - uspostnews.com
Verona Pharma Plc ADR [VRNA] Rickard Kathleen A. sells 79,264 Shares for $0.66 million - knoxdaily.com
Verona Pharma Plc ADR [VRNA] Chief Medical Officer makes an insider purchase of 79,264 shares worth 0.66 million. - knoxdaily.com
Verona Pharma secures $450 million credit facility on better terms By Investing.com - Investing.com South Africa
Verona Pharma secures $450 million credit facility on better terms - Investing.com
Xeris Biopharma reshuffles board, appoints new director - Investing.com
The growth track for Cracker Barrel Old Country Store Inc (CBRL) has changed recently - SETE News
Verona Pharma Plc ADR (NASDAQ: VRNA) Up 298.80% This Year: What Is Going To Happen Next - Stocks Register
Verona Pharma’s chief medical officer sells shares worth $661,941 - Investing.com India
Verona Pharma’s chief medical officer sells shares worth $661,941 By Investing.com - Investing.com South Africa
Keeping an Eye on Gilead Sciences, Inc (GILD) After Insider Trading Activity - Knox Daily
McEwen Mining Inc (MUX) Becoming More Attractive for Investors - Knox Daily
Morgan Stanley Upgrades Solaredge Technologies Inc (SEDG) to an Equal-weight from an Underweight - Knox Daily
Verona Pharma at Leerink Global Healthcare: Eutuvera’s Promising Launch By Investing.com - Investing.com UK
Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts By Investing.com - Investing.com South Africa
Verona Pharma stock surges as Q4 revenue soars past estimates - Investing.com India
Verona Pharma stock surges as Q4 revenue soars past estimates By Investing.com - Investing.com Canada
Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts - Investing.com
Verona Pharma plc (NASDAQ:VRNA) Q4 2024 Earnings Call Transcript - MSN
Verona Pharma ADR earnings beat by $0.02, revenue topped estimates - Investing.com UK
A company insider recently sold 640,264 shares of Verona Pharma Plc ADR [VRNA]. Should You Sale? - Knox Daily
Verona Pharma stock soars to all-time high of $62.09 - Investing.com India
Verona Pharma stock soars to all-time high of $62.09 By Investing.com - Investing.com South Africa
Verona Pharma Plc Adr Azioni (VRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):